DBV Technologies (NASDAQ:DBVT) Price Target Increased to $7.00 by Analysts at HC Wainwright

DBV Technologies (NASDAQ:DBVT) had its price target upped by HC Wainwright from $5.00 to $7.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright also issued estimates for DBV Technologies’ FY2024 earnings at ($1.41) EPS, FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($0.50) EPS.

DBVT has been the subject of several other reports. JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of DBV Technologies in a research note on Tuesday, September 24th. StockNews.com assumed coverage on shares of DBV Technologies in a research report on Monday, October 21st. They set a “hold” rating for the company.

DBV Technologies Stock Performance

DBV Technologies stock opened at $0.87 on Thursday. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $2.28. The firm has a market capitalization of $83.61 million, a PE ratio of -1.03 and a beta of 0.67. The business’s 50-day simple moving average is $0.77 and its 200-day simple moving average is $0.96.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. During the same period in the prior year, the firm earned ($0.26) earnings per share. Research analysts forecast that DBV Technologies will post -1.43 earnings per share for the current year.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to its most recent filing with the SEC. The firm owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the period. DBV Technologies makes up about 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. 71.74% of the stock is owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.